# Alexis Borisy

> Alexis Borisy is a Series A investor at Curie.Bio (Boston) backing Biotechnology and Health Care. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Curie.Bio](https://shizune.co/investors/profile/curie-bio)
- Location: Boston, United States
- Total investments: 14
- Last investment: Mar 2022
- Lead investor: 21%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/alexis-borisy-577a2ab6/

Alexis Borisy is a Series A investor at Curie.Bio in Boston focused on Biotechnology and Health Care. Alexis Borisy is the Co-Founder and Chairman of Curie.Bio. He previously worked at Thrive Earlier Detection Corp. as a Board Of Directors. Alexis Borisy attended Harvard University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 43% |
| Health Care | 5 | 36% |
| Genetics | 4 | 29% |
| Medical | 3 | 21% |
| Life Science | 1 | 7% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 36% |
| Series B | 5 | 36% |
| Series C | 2 | 14% |
| Private Equity | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Celsius Therapeutics | Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning. | $83M | Series B | Mar 24, 2022 |  |
| Insitro | Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $400M | Series C | Mar 15, 2021 |  |
| Insitro | Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $143M | Series B | May 26, 2020 |  |
| Insitro | Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $100M | Series A | Apr 16, 2019 |  |
| Celsius Therapeutics | Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning. | $65M | Series A | May 15, 2018 |  |
| Insitro | Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $100M | Series A | May 02, 2018 |  |
| Editas Medicine | Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translateearly findings into viable human therapeutic products.Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado. | $120M | Series B | Aug 10, 2015 |  |
| Blueprint Medicines | Blueprint Medicines develops targeted therapies for cancer and blood disorders, focusing on precision medicine. The company utilizes genetic insights to design treatments tailored to individual patient needs. Their portfolio includes products aimed at specific mutations and conditions, enhancing treatment options for patients with various types ofcancer and hematologic diseases. Blueprint Medicines collaborates with healthcare providers to ensure that their therapies are accessible and effectively integrated into patient care. Through ongoing research and development, the company aims to expand its offerings and address unmet medical needs in oncology and hematology. | $50M | Series C | Nov 12, 2014 |  |
| Blueprint Medicines | Blueprint Medicines develops targeted therapies for cancer and blood disorders, focusing on precision medicine. The company utilizes genetic insights to design treatments tailored to individual patient needs. Their portfolio includes products aimed at specific mutations and conditions, enhancing treatment options for patients with various types ofcancer and hematologic diseases. Blueprint Medicines collaborates with healthcare providers to ensure that their therapies are accessible and effectively integrated into patient care. Through ongoing research and development, the company aims to expand its offerings and address unmet medical needs in oncology and hematology. | $25M | Series B | Jan 07, 2014 |  |
| Editas Medicine | Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translateearly findings into viable human therapeutic products.Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado. | $43M | Series A | Nov 25, 2013 |  |

10 of 14 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 5 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 4 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 4 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 4 deals together
- [Two Sigma Ventures](https://shizune.co/investors/profile/two-sigma-ventures) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together

## About Curie.Bio

VC Fund

Curie.Bio is a founder-focused seed-stage venture capital firm.

4 contacts available at Curie.Bio.

| Name | Title | Profile |
| --- | --- | --- |
| Alexis Borisy | Co-Founder & Chairman | https://shizune.co/investors/profile/alexis-borisy |
| Zach Weinberg | Co-Founder and CEO | https://shizune.co/investors/profile/zach-weinberg |
| Ben Auspitz | Managing Partner, Breakout Fund | https://shizune.co/investors/profile/ben-auspitz |
| Christoph Lengauer | Co-Founder and CSO | https://shizune.co/investors/profile/christoph-lengauer |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Alexis Borisy invest in?

Alexis Borisy invests primarily in Biotechnology, Health Care and Genetics startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alexis Borisy last invest?

The most recent investment recorded for Alexis Borisy closed in Mar 2022. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co